MAb biosimilars for solid tumours: Perspectives for pharmacists

touchEXPERT OPINIONS for touchONCOLOGY Listen to leading experts discuss how monoclonal antibody (MAb) biosimilars for solid tumours are developed and approved, and learn about the practical aspects of their use in oncology pharmacy. The experts Dr Paul Cornes - Comparative Outcomes Group, Bristol, UK Dr Joseph Bubalo - Oregon Health & Science University Hospital & Clinics, Portland, USA Mr Hisanaga Nomura - Japan Agency for Medical Research and Development, Tokyo, Japan This touchPODCAST is for HCPs only. This activity is funded by an unrestricted independent medical educational grant from Pfizer. This activity is provided by touchIME. For further information visit our website: https://touchoncology.com/education/mab-biosimilars-in-the-treatment-of-solid-tumours-perspectives-for-pharmacists/